John Evans Chief Executive Officer and Board Member
John Evans joined Beam in 2017 as CEO, bringing significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry. Mr. Evans is also a Venture Partner with ARCH Venture Partners.
Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals (AGIO), most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. At Agios, Mr. Evans served as IDH Portfolio Executive, providing strategic and operational leadership for a portfolio of first-in-class IDH inhibitors including IDHIFA (AG-221) and AG-120. He helped initiate and lead Agios’s landmark alliance with Celgene, resulting in over $600M of funding and investments across multiple innovative research collaborations in cancer metabolism. He also initiated and co-led Agios’s strategic expansion into rare genetic diseases of metabolism. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals as program executive for the company’s Hsp90 inhibitors. He has also worked at McKinsey & Company (Pharmaceuticals practice), MedImmune, and Bayer Pharmaceuticals.
Mr. Evans holds an M.B.A. in Healthcare Management from Wharton, a Masters in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.